Viral Vaccine For Bovine Species (e.g., Cattle, Etc.) Patents (Class 424/813)
  • Patent number: 8895029
    Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Carol L. Rinehart
  • Patent number: 8440203
    Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 14, 2013
    Assignee: Intervet Inc.
    Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
  • Patent number: 7078388
    Abstract: DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal species considered, under conditions allowing the in vivo expression of this sequence, and a cationic lipid containing a quaternary ammonium salt, of formula in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: July 18, 2006
    Assignee: Merial
    Inventors: Jean-Christophe Francis Audonnet, Laurent Bernard Fischer, Simona Barzu-Le-Roux
  • Patent number: 6660262
    Abstract: A new and improved formulation and method for making same, for a broad spectrum antimicrobial treatment for bacterial and viral infections in cattle, horses, pigs, sheep and other domestic and non-domestic animals. More particularly, the present invention relates to a treatment which enables rapid relief of symptoms in an affected animal with a mortality of less than 1 percent by providing trace organic minerals in microgram quantities which act as nutrients for the animal. The treatment provides further nutritional requirements in the form of vitamin A, folic acid and vitamin D3 supplements, cobalt amino acid chelates and dried kelp, a source of minerals, amino acids, simple and complex carbohydrates, iodine and fiber. In addition, a bacterial innoculum consisting of Acidophilus species is introduced which would inhibit growth of pathogenic or opportunistic species of bacteria by competition for nutrients as well as providing for required vitamins as a by-product of metabolism.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: December 9, 2003
    Assignee: Bovine Health Products, Inc.
    Inventor: Randy R. McKinney
  • Patent number: 6458586
    Abstract: The invention provides cell lines capable of supporting the replication of a defective recombinant virus vector. In one aspect, bovine cell lines expressing adenovirus E1 functions are provided. The cell lines are useful for the propagation of adenovirus vectors with mutations and/or deletions in E1 and other essential regions of the adenovirus genome.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: October 1, 2002
    Assignee: University of Saskatchewan
    Inventors: Suresh Kumar Tikoo, Lorne A. Babiuk, Police Seshidhar Reddy
  • Patent number: 6376473
    Abstract: Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: April 23, 2002
    Assignee: Merial
    Inventors: Jean-Christophe Audonnet, Annabelle Bouchardon, Philippe Baudu, Michel Riviere
  • Patent number: 6270800
    Abstract: A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: August 7, 2001
    Assignee: Pfizer Inc.
    Inventors: Tully J. Speaker, H. Fred Clark, Charlotte A. Moser, Paul A. Offit, Manuel Campos, Patrick J. Frenchick
  • Patent number: 6224878
    Abstract: A recombinant virus is provided which is obtained from a BHV virus originally having the gI gene whose DNA sequence is delimited by nucleotides 172 and 1311 of SEQ ID NO:1 herein and which has been mutated by total or partial deletion and/or insertion in this region. By the mutation in this region, there is no longer any expression of the glycoprotein which has been mutated or rendered inactive, and thus animals vaccinated with these mutants do not develop antibodies against the glycoprotein and can be serologically distinguished from animals infected by field BHV-1 strains and other vaccinal strains currently used. A method of using the present recombinant virus is also provided which allows one to distinguish infected animals from vaccinated animals in a manner that has not previously been possible using presently available commercial vaccines.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: May 1, 2001
    Assignee: Merial
    Inventors: Patricia Leung-Tack, Isabelle Christine Marie-Andrée Legastelois, Jean-Christophe Francis Audonnet, Michel Emile Albert Riviere
  • Patent number: 6136781
    Abstract: The LH-RH receptor antagonists containing cyclic pentapeptides or salts thereof and novel cyclic pentapeptide or salts thereof are provided.The LH-RH receptor antagonists of the present invention are effective as medicines for preventing and curing sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, mammary cancer, pituitary tumor, etc.), prostatomegaly, endometriosis, hysteromyoma, puberty precox, amenorrheal syndromes, multilocular ovarian syndromes, comedo, etc. and are also effective as pregnancy controlling agents (e.g., contraceptives, etc.) and menstrual cycle controlling agents. Moreover, these are also useful in the livestock industry for the control of the estrus of animals and also for the improvement in the quality of meat and for the control of the growth of animals, as well as in the marine products industry as spawning promoters for fishes.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: October 24, 2000
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Chieko Kitada, Shuichi Furuya, Koichi Kato
  • Patent number: 5928649
    Abstract: A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inducer, are administered in conjunction with the combination vaccine. The cytokine or cytokine inducer can be administered concurrently with or subsequently to the vaccine, and can be recombinantly produced or isolated from cell culture.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 27, 1999
    Assignee: American Cyanamid Company
    Inventors: Michael Joseph Daley, Phillip Wayne Hayes
  • Patent number: 5462734
    Abstract: A vaccination kit and protocol for using it are disclosed which results in immunity from infection by herpesvirus. A first formulation of an isolated viral glycoprotein is injected intramuscularly to result in systemic immunity. Later a second formulation including the isolated viral glycoprotein with an adjuvant is administered intranasally, or otherwise administered to the mucosal membranes. A level of both systemic and mucosal immunity is achieved such that viral infection, as well as symptomatic disease, is avoided. The method and the vaccine are exemplified by a vaccine for Bovine Herpesvirus 1.
    Type: Grant
    Filed: March 22, 1993
    Date of Patent: October 31, 1995
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Geoffrey J. Letchworth, III, Barbara A. Israel